Toxicity of the topoisomerase I inhibitors

Expert Opinion on Drug Safety

Volumn 4, Issue 1, 2005, Pages 45-53

  Seiter, Karen ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Irinotecan; Topoisomerase I inhibitor; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ACETORPHAN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ATROPINE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HOMOCAMPTOTHECIN; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; QUINOLONE DERIVATIVE; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APLASIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIAPHORESIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LACRIMATION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEIOSIS; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; RASH; REVIEW; RHINITIS; SALIVATION; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; RENAL INSUFFICIENCY; TOPOTECAN;

EID: 12544256413     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.1.45     Document Type: Review

References (63)

1. GUPTA M, FUJIMORI A, POMMIER Y: Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta (1995) 1262:1-14.
2. KOHN KW, POMMIER Y: Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann. NY Acad. Sci. (2000) 922 11-26.
3. SORDET O, KHAN QA, KOHN KW, POMMIER Y: Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents (2003) 3:271-290.
4. WALL ME, WANI MC, COOK CE, PALMER KH: Plant antitumour agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumour inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. (1966) 88:3888-3890.
5. MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. (1972) 56 95-101.
6. HSIANG YH, HERTZBERG R, HECHT S, LIU LF: Camptothecin induces protein-linked DNA breaks via mammalian topoisomerase I. J. Biol. Chem. (1985) 260:14873-14878.
7. KINGSBURY WD, BOEHM JC, JAKAS DR et al.: Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumour activity. J. Med. Chem. (1991) 34 98-107.
8. LAVERGNE O, LESUER-GINOT L, PLA RODAS F et al.: Homocamptothecins: synthesis and antitumour activity of novel E-ring-modified camptothecin analogues. J. Med. Chem. (1998) 41 5410-5419.
9. GELDERBLOM H, SALAZAR R, VERWEIJ J et al.: Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumours. Clin. Cancer Res. (2003) 9:4101-4107.
10. ROUGIER P, BUGAT R, DOUILLARD JY et al.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. (1997) 15 251-260.
11. ROTHENBERG ML, ECKARDT JR, KUHN JG et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. (1996) 14:1128-1135.
12. PITOT HC, WENDER DB, O'CONNELL MJ et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol. (1997) 15:2910-2919.
13. SHIMADA Y, YOSHINO M, WAKUI A et al.: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J. Clin. Oncol. (1993) 11:909-913.
14. FUKUOKA M, NIITANI H, SUZUKI A et al.: A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. (1992) 10:16-20.
15. MASUDA N, FUKUOKA M, KUSUNOKI Y et al.: CPT-11: a new derivative of camptothecin for the treatment of reftactory or relapsed small-cell lung cancer. J. Clin. Oncol. (1992) 10:1225-1229.
16. OHNO R, OKADA K, MASAOKA T et al.: An early Phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukaemia and lymphoma. J. Clin. Oncol. (1990) 8:1907-1912.
17. SALIBA F, HAGIPANTELLI R, MISSET JL et al.: Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patient with advanced colorectal cancer a prospective assessment. J. Clin. Oncol. (1998) 16:2745-2751.
18. BENSON AB, AJANI JA, CATALANO RB et al.: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. (2004) 22:2918-2926.
19. FUCHS CS, MOORE MR, HARKER G et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. (2003) 21 807-814.
20. TSAVARIS N, ZIRAS N, KOSMAS C et al.: Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother. Pharmacol. (2003) 52 514-519.
21. CUNNINGHAM D, PYRHÔNEN S, JAMES RD et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet (1998) 352:1413-1418.
22. ROUGIER P, VAN CUTSEM E, BAJETTA E et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 352:1407-1412.
23. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomised trial. Lancet (2000) 355:1041-1047.
24. SALTZ LB, KANOWITZ J, KEMENY NE et al.: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patient with advanced solid tumours. J. Clin. Oncol. (1996) 14:2959-2967.
25. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
26. ROTHENBERG ML, MEROPOL NJ, POPLIN EA et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. (2001) 19 3801-3807.
27. ANDRE T, LOUVET C, MAINDRAULT-GOEBEL F et al.: CPT-11 (irinotecan) addition to bimonthly, high-dose leucavorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur. J. Cancer (1999) 35 1343-1347.
28. MABRO M, LOUVET C, ANDRE T et al.: Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am. J. Clin. Oncol. (2003) 26:254-258.
29. GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:23-30.
30. SATOH T, HOSOKAWA M, ATSUMI R et al.: Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumour agent, by carboxylesterase. Biol. Pharm. Bull. (1994) 17:662-664.
31. KUDOH S, FUKUOKA M, MASUDA N et al.: Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn. J. Cancer Res. (1995) 86:406-413.
32. BARILERO I, GANDIA D, ARMAND JP et al.: Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography. application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr. (1992) 575:275-280.
33. ROWINSKY EK, GROCHOW LB, ETTINGER DS et al.: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. (1994) 54:427-436.
34. INNOCENTI F, UNDEVIA SD, IYER L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropaenia of irinotecan. J. Clin. Oncol. (2004) 22 1382-1388.
35. MEYERHARDT JA, KWOK A, RATAIN MJ et al.: Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:1439-1446.
36. VENOOK AP, ENDERS KLEIN C, FLEMING G et al.: A Phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann. Oncol. (2003) 14:1783-1790.
37. RAYMOND E, BOIGE V, FAIVRE S et al.: Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol. (2002) 20:4303-4312.
38. CANAL P, GAY C, DEZEUZE A et al.: Pharmacokinetic, and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. (1996) 14:2688-2695.
39. GUPTA E, MICK R, RAMIREZ J et al.: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol. (1997) 15:1502-1510.
40. VASSAL G, DOZ F, FRAPPAZ D et al.: A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumours. J. Clin. Oncol. (2003) 21:3844-3852.
41. MUGISHIMA H, MATSUNAGA T, YAGI K et al.: Phase I study of irinotecan in pediatric patients with malignant solid tumours. J. Pediatr. Hematol. Oncol. (2002) 24:94-100.
42. GILBERT MR, SUPKO JG, BATCHELOR T et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. (2003) 9:2940-2949.
43. RIBRAG V, KOSCIELNY S, VANTELON JM et al.: Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk. Lymphoma (2003) 44:1529-1533.
44. RIBRAG V, SUZAN F, RAVOET C et al.: Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukaemia (2003) 17:319-322.
45. SARRIS AH, PHAN A, GOYA et al.: irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a Phase II trial. Oncology (2002) 16:27-31.
46. ROWINSKY EK, GROCHOW LB, SARTORIUS SE et al.: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumours. J. Clin. Oncol. (1996) 14:1224-1235.
47. CREEMERS GJ, BOLIS G, GORE M et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J. Clin. Oncol. (1996) 14:3056-3061.
48. SCHILLER JH, KIM K, HUTSON P et al.: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol. (1996) 14:2345-2352.
49. ARDIZZONI A, HANSEN H, DOMBERNOWSKY P et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. (1997) 15:2090-2096.
50. MACDONALD JS, BENEDETTI JK, MODIANO M, ALBERTS DS: Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Invest. New Drugs (1997) 15:357-359.
51. TEN BOKKEL HUININK W, GORE M, CARMICHAEL J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. (1997) 15:2183-2193.
52. VON PAWEL J, SCHILLER JH, SHEPHERD FA et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. (1999) 17 658-667.
53. HOCHSTER H, WADLER S, RUNOWICZ C et al.: Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (1999) 17:2553-2561.
54. HOCHSTER H, LIEBES L, SPEYER J et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. (1994) 12 553-559.
55. KANTARJIAN HM, BERAN M, ELLIS A et al.: Phase I study of topotecan, a new topoisomerase I inhibitor, in patient with refractory or relapsed acute leukaemia. Blood (1993) 81:1146-1151.
56. BERAN M, KANTARJIAN H, O'BRIEN S et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukaemia. Blood (1996) 88 2473-2479.
57. BERAN M, ESTEY E, O'BRIEN S et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukaemia. J. Clin. Oncol. (1999) 17 2819-2830.
58. SCHILDER RJ, GALLO JM, MILLENSON MM et al.: Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J. Clin. Oncol. (2001) 19:1183-1194.
59. PRINCE HM, RISCHIN D, QUINN M et al.: Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Gynecol. Oncol. (2001) 81:216-224.
60. KUSHNER BH, CHEUNG NK, KRAMER K et al.: Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumours, and other poor risk solid tumours in children and young adults. Bone Marrow Transplant (2001) 28 551-556.
61. DONATO ML, ALEMAN A. CHAMPLIN RE et al.: High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk. Lymphoma (2004) 45:755-759.
62. O'REILLY S, ROWINSKY EK, SLICHENMYER W et al.: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. (1996) 14:3062-3073.
63. O'REILLY S, ROWINSKY E, SLICHENMYER W et al.: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. (1996) 88:817-824.